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Summary We examined bone marrow aspirates from 100 metastasis-free primary breast cancer patients. In
38/100 patients (38%), tumour cells were detected in the marrow using an immunocytochemical technique with
a cocktail of two monoclonal antibodies: anti-EMA and anti-cytokeratin. Median follow-up was 34 months:
15/38 (39%) tumour cell-positive patients have since relapsed, but only 9/62 (15%) tumour cell-negative
patients. The median interval between tumour cell detection and relapse was 11.4 months. No statistically
significant correlation existed between tumour cell presence and 'established' prognostic factors. However,
relapse-free survival was significantly shorter in tumour cell-positive patients. Multivariate analysis showed
tumour cell presence as a strong, significant prognostic factor for relapse-free as well as overall survival. We
conclude that screening for tumour cells in bone marrow of primary breast cancer patients identifies high-risk
patients for early relapse. In particular, patients with node-negative tumours who have tumour cells in their
bone marrow may require subsequent systemic therapy.
Six to nine per cent of white women in Europe and North
America will develop breast cancer in their lifetime. Resear-
chers in the USA even talk about a breast cancer epidemic
(Greenspan, 1987). Despite all progress made over the last
decades in diagnosis and treatment, overall survival has not
significantly increased. The median 10-year survival rate is
still less than 50% (Henderson & Canellos, 1980). Even
among a presumably 'low-risk' population like node-negative
patients there is a death rate of about 25% over a decade
(McGuire et al., 1989).
At primary therapy less than 10% of all breast cancer
patients present with clinically detectable distant tumour
spread (Henderson & Canellos, 1980). Therefore, indirect
prognostic criteria such as tumour size, lymph node and
receptor status, grading or DNA analysis are used to charac-
terise the individual patient's risk for relapse. Based on this
risk analysis, adjuvant systemic therapy is administered.
Potentially severe short- and long-term side-effects might be
associated with adjuvant therapy. However, recent reports
demand an even larger group of patients (i.e. node-negative
ones) to be treated in an adjuvant setting (Fisher et al.,
1989a; Ludwig Breast Cancer Study Group, 1989). Better
prognostic criteria are therefore urgently needed to identify
those patients who will actually benefit from adjuvant
therapy. This would allow a more individualised risk-benefit
analysis (McGuire et al., 1990).
One approach to such an improved risk analysis is the
search for micrometastatic tumour spread at primary
therapy. The skeletal system is the predominant relapse loca-
tion in breast cancer (Coombes et al., 1983). It is therefore
quite obvious to search there for early distant spread. Con-
ventional biopsies enabled tumour cell detection in the bone
marrow of 3.9% apparently metastasis-free patients (Ridell &
Landys, 1979).
This percentage was considerably raised by the use of
immunocytochemical methods (Dearnaley et al., 1981).
Encouraged by the results of the London group from the
Ludwig Institute (Dearnaley et al., 1981; Redding et al.,
1983), our group started in 1984 to screen for tumour cells in
the bone marrow of primary breast cancer patients. After a
median follow-up of almost 3 years, we now seek to evaluate
the significance of this tumour cell detection as a new prog-
nostic factor in breast cancer.
Patients and methods
Patients
From October 1984 until February 1990, 115 primary breast
cancer patients between the age of 32 and 77 years (median
54 years) were entered into this study. Before surgery, all
patients were screened for distant metastases by clinical
examination, blood tests [CEA, CA 15-3, 'y-glutylamyltrans-
ferase (y-GT), alkaline phosphatase (AP)], liver ultrasound,
chest radiography and bone scan. Fifteen patients with overt
metastases (i.e. stage Ml) were excluded from further statis-
tical evaluation. Depending on the size of the tumour, all
patients underwent either modified radical mastectomy or
breast-preserving surgery (with subsequent radiation) as well
as axillary lymph node dissection. Bone marrow aspirates
were taken immediately after surgery from six sites: upper
and lower sternum as well as left and right anterior and
posterior iliac crest. Hormone receptor status of the primary
tumour was determined either by DCC (dextran charcoal
assay) or by immunohistochemistry ('ERICA', Abbot,
Chicago, USA).
All patients had their primary treatment as well as their
follow-up visits at our hospital. Thus, a consistency of treat-
ment was achieved. Every node-positive patient received
either adjuvant chemo- (standard CMF) or adjuvant hor-
mone (tamoxifen) therapy depending on receptor status and
menopausal state. After primary therapy, patients had
regular check-ups with thorough clinical examination and
blood tests (CEA, CA-153, AP, y-GT) every 3 months, as
well as a chest radiography and a liver ultrasound every 6
months, and a bone scan every year.
Immunocytochemical stainingprocedure
From each aspiration site 4-6 ml of bone marrow was taken.
In the first 16 patients the aspirates of each site were
analysed separately. However, no correlation between aspira-
tion site and relapse location could be found. Therefore, we
then started to pool the aspirates for further preparation.
The bone marrow suspension was separated on a Lympho-
prep gradient (density 1.077) as described by Boyum (1968).
The interphase layer was separated, washed, resuspended and
smeared onto 20-40 glass slides at a final concentration of
about 2 x I0O cells ml-'. The slides were then wet fixed in
absolute ethanol and stored at - 20'C. For the staining
procedure we modified the technique introduced by Dear-
naley et al. (1981). We used the following monoclonal
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primary antibodies rather than polyclonal antibodies for the
indirect immunocytochemical staining procedure:
(1) anti-EMA (clone E-29, Dako, Hamburg, Germany);
(2) a cocktail of two monoclonal antibodies, anti-EMA
(see above) and anti-cytokeratin (Moll's No. 8, 18, 19,
Becton Dickinson, Heidelberg, Germany);
(3) 12-H-12, a biotinylated antibody against the breast
cancer associated glycoprotein TAG-12 (kindly pro-
vided by Professor Kaul, Heidelberg University, Ger-
many).
After blocking endogenous alkaline phosphatase activity
with 20% acetic acid and 2.28% periodic acid, the slides were
incubated with the primary antibodies. Subsequently the
secondary antibody was applied - a rabbit anti-mouse
antibody conjugated to alkaline phosphatase (Dako, Ham-
burg, Germany). For the 12-H-12 antibody, alkaline
phosphatase-labelled avidin was used instead. Between the
staining steps, the slides were washed in PBS buffer. As
substrate for visualisation we used fast red TR salt (Sigma,
Munich, Germany) dissolved in Tris buffer pH 8.2 and
naphthol-AS-MX-phosphate (in N-N-dimethylformamide),
adding 2% levamisole to again block endogenous alkaline
phosphatase activity. The slides were then counterstained
with Mayer's haemalaun and coverslips applied. To facilitate
screening of the slides, we evaluated them on a monitor
linked to an automatic slide table ('Prodyscope', Will, Wetz-
lar, Germany). Cells were only classified as tumour cells if
they showed immunocytochemical staining as well as the
morphological criteria of tumour cells.
Statistical methods
Statistical data evaluation was performed with the EDA
('easy data analysis') software package (Professor K6pcke,
IBE, Munich, Germany, 1989). A 95% confidence interval
was used for all statistical tests. Thus, only P-values <0.05
were considered to be statistically significant. The X2-method
was applied to assess the correlation between tumour cell
detection and 'established' prognostic factors. Analysis and
plotting of survival data was performed by means of the
Kaplan-Meier estimate. The Mantel-Cox test was used for
calculation of survival probabilities (Kaplan & Meier, 1958).
Optimal cut-off values for the prognostic factor 'tumour
size', i.e. for classification of 'small' and 'large' tumours were
calculated by the CART method (classification and regres-
sion trees) (Segal & Bloch, 1989) and the maximum likeli-
hood method. To compare the predictive value of the prog-
nostic factors for relapse-free as well as overall survival, we
performed a multivariate analysis applying 'Cox's propor-
tional hazard model' (Cox, 1972) and the BMDP software
package (Dixon, 1981).
Results
Tumour cell detection
At the time of primary therapy, tumour cells in the bone
marrow were detected in 38 of the 100 breast cancer patients
(38%) without clinically detectable metastases (i.e. stage
MO).
Correlation with establishedprognosticfactors
Table I shows the correlation between tumour cell presence
in the bone marrow and 'established' prognostic factors:
tumour size, lymph node involvement, menopausal state,
receptor status, grading and histological type of the tumour.
Table I Correlation between detection of tumour cells in the bone marrow and other
prognostic factors (100 patients at stage MO)
Tumour cell Tumour cell
positive negative Correlation
Prognostic factor (n = 38) (n = 62) (X2 test)
Tumour size P = 0.65
pTI (n = 47) 18 (38%) 29 (62%)
pT2 (n = 36) 12 (33%) 24 (67%)
pT3 (n = 6) 2 4
pT4 (n = 8) 5 3
pTx (n = 3) 1 2
Lymph node status P = 0.24
pNO (n = 39) 19 (49%) 20 (51%)
1-3 lymph nodes (n = 28) 7 (25%) 21 (75%)
>3 lymph nodes (n = 32) 11(34%) 21 (66%)
pNx (n = 1) 1 0
Oestrogen receptor P = 0.40
Positive (n = 56) 18 (32%) 38 (68%)
Negative (n = 31) 14 (45%) 17 (55%)
Not tested (n = 13) 6 7
Progesterone receptor P = 0.73
Positive (n = 38) 15 (39%) 23 (61%)
Negative (n = 49) 17 (35%) 32 (65%)
Not tested (n = 13) 6 7
Menopausal state P = 0.33
Premenopausal (n = 51) 17 (33%) 34 (67%)
Post-menopausal (n = 49) 21 (43%) 28 (57%)
Grading P = 0.35
GI (n = 2) 0 2
G2 (n = 62) 25 (40%) 37 (60%)
G3 (n = 27) 8 (30%) 19 (70%)
Gx (n = 9) 5 4
Histological type P = 0.13
Ductal carcionoma (n = 71) 22 (31%) 49 (69%)
Lobular carcinoma (n = 11) 8 3
Inflammatory carcinoma (n = 3) 1 2
Other (n = 15) 7 8568 N. HARBECK et al.
Patients under the age of 50 years were classified as
premenopausal and patients of 50 years and older as post-
menopausal. None of the prognostic factors showed a statis-
tically significant correlation with the presence of tumour
cells.
Correlation withfollow-up data
Metastasis Table II shows the correlation between tumour
cell presence and patient outcome over a median follow-up
period of 34 months (maximum 65 months, minimum 7
months). Of the total of 100 patients, 24 (24%) have already
relapsed, 14 (14%) at distant sites. Tumour cell-positive
patients were at significantly higher risk (P = 0.016) for
relapse than tumour cell-negative patients (39% vs 15%). The
relapse-free survival data of tumour cell-positive and tumour
cell-negative patients is plotted in Figure 1. Nine of the 38
(24%) tumour cell-positive patients have since relapsed at
distant sites compared with 5/62 (8.1%) tumour cell-negative
patients. Up till now, no tumour cell-negative patient has
relapsed solely in the skeletal system; only one tumour cell-
negative patient has relapsed in bone and visceral sites simul-
taneously. In comparison, in seven tumour cell-positive
patients the first site of relapse was bone, in six of whom
relapse occurred solely in the skeletal system (see Table II).
This difference is highly significant (P = 0.008). Additionally,
within the subgroup of oestrogen receptor-positive patients
(n = 56), tumour cell presence in the bone marrow also had a
significant impact on survival: relapse-free (P = 0.0086) as
well as overall survival (P = 0.0271) was significantly shorter
in tumour cell-positive, oestrogen receptor-positive patients.
The median interval between tumour cell detection in the
bone marrow and metastasis is 11.4 months (maximum 28
months, minimum 1 month). In total, the median relapse-free
survival time was 28 months. However, tumour cell-positive
patients had a significantly shorter relapse-free survival than
tumour cell-negative ones: 19 months vs 33 months
(P = 0.0011) (see Table II).
Survival The overall survival data can be seen in Table III.
Sixteen of the total of 100 patients (16%) have already died:
nine (24%) in the tumor cell-positive group and seven (11%)
in the tumour cell-negative group. In total, the median
overall survival time was 33 months, 29 months for tumour
cell-positive patients and 36 months for tumour cell-negative
patients. The impact of tumour cell presence on overall
survival has not yet reached statistical significance
Table II Relapse after tumour cell detection in the bone marrow
(100 initially metastasis-free patients)
Tumour cell Tumour cell
positive negative
(n =38) (n =62)
Relapse (all locations)
Node-negative patients (n = 39) 5/19 1/20
Node-positive patients (n = 61) 10/19 8/42
All patients (n = 100): 24% 15/38 (39%) 9/62 (15%)
Site of relapse
Bone 6 0
Visceral (lung, liver) 2 3
Soft tissue (skin, nodes) 0 1
Mixed (bone + visceral) 1 1
Distant relapse (n = 14): 14% 9 (24%) 5 (8.1%)
Local relapse (n = 10): 10% 6 (16%) 4 (6.5%)
Timea between tumour cell 11.4 months
detection and relapse
Relapse-free survival' 19 months 33 months
all patients: 28 months
aMedian period.
(P
= 0.0826). Figure 2 shows the overall survival curves of
tumour cell-positive and tumour cell-negative patients.
Node-negative patients A total of 39/100 patients (39%)
were free of lymph node involvement at the time of primary
therapy. In this subgroup of patients, the percentage tumour
cell detection was 49%. A significant correlation existed only
between histological type of the primary tumour and tumour
cell presence and 'established' prognostic factors in NO
patients. Table IV shows the follow-up data of all 39 node-
negative patients. The correlation between tumour cell
presence and patient follow-up coincides with the findings in
the total population of MO patients (see Tables II and III):
tumour cell-positive patients tend to have a worse outcome
than tumour cell-negative ones.
Multivariate analysis
Only those prognostic factors exhibiting at least borderline
significance for relapse-free or overall survival in the
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Figure 1 Tumour cell presence in the bone marrow and relapse-
free survival (RFS) in primary breast cancer (n = 100).
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Figure 2 Tumour cell presence in the bone marrow and overall
survival (OS) in primary breast cancer (n = 100).
Table III Overall survival after tumour cell detection in the bone
marrow (100 patients, initially at stage MO)
Tumour cell Tumour cell
positive negative
(n
= 38) (n = 62)
Overall survivala
All patients: 33 months 29 months 36 months
Deceased
Total 16 patients (16%) 9 (24%) 7 (11%)
aMedian period.TUMOUR CELLS IN MARROW OF PRIMARY BREAST CANCER PATIENTS 569
univariate Kaplan-Meier test were considered for multi-
variate analysis. Since there was a highly significant correla-
tion between tumour size and lymph node status
(P = 0.0007), only the clinically more important of these two
factors, i.e. lymph node status, was entered into multivariate
analysis.
Absence of tumour cells in the bone marrow was the
strongest predictor for relapse-free survival (P = 0.0005),
even stronger than lymph node status (P = 0.0367). The
remaining two parameters, grading and oestrogen receptor
status, showed no statistical significance for relapse-free sur-
vival (see Table Va).
Histopathological grading had the highest significant
impact (P = 0.0027) on overall survival, closely followed by
tumour cell presence (P = 0.0170). However, lymph node
involvement and oestrogen receptor status were not statis-
tically significant for the prediction of overall survival (see
Table Vb).
Discussion
The percentage of tumour cell-positive patients (38%) in this
study is slightly higher than in our earlier publications
Table IV Follow-up data in node-negative patients (39 patients,
initially at stage MO)
Tumour cell Tumour cell
positive negative
(n = 19) (n =20)
Relapse (all locations) 5
Site of first relapse
Bone 2 0
Other 3 1
Time between tumour cell 9.6 months -
detection and metastasisa
Relapse-free survival' 19 months 37 months
Deceased 3 1
Overall survivala 30 months 38 months
'Median period.
Table Va Relapse-free survival in primary breast cancer (n = 100):
multivariate analysis of various prognostic factors
Univariate Multivariate Relative risk
Prognostic factor P-value P-value (95% CI)a
Tumour cell presence 0.0011 0.0005 4.1 (1.8-9.1)
(yes/no)
Nodal status 0.0448 0.0367 2.5 (1.0-6.2)
(positive/negative)
ER status 0.0609 0.2310
(positive/negative)
Grading 0.2585 0.2396
(GI -2/G3)
aConfidence interval.
Table Vb Overall survival in primary breast cancer (n = 100):
analysis of various prognostic factors
Univariate Multivariate Relative risk
Prognostic factor P-value P-value (95% CI)'
Grading 0.0075 0.0027 4.7 (1.5-33.4)
(GI -2/G3)
Tumour cell presence 0.0826 0.0170 3.7 (1.3-10.5)
(yes/no)
Nodal status 0.0617 0.0730 2.8 (0.8-10.2)
(positive/negative)
ER status 0.0493 0.1404
(positive/negative)
aConfidence interval.
(Harbeck et al., 1987; Untch et al., 1988) or the percentage
reported by some other groups (Mansi et al., 1987; Schlimok
et al., 1987; Porro et al., 1988; Ellis et al., 1989; Diel et al.,
1990). One explanation might be an improved detection rate
by using an antibody cocktail instead of a single monoclonal
antibody. Using a similar antibody cocktail, Cote et al.
(1991) found a similar detection rate of 37%. Unspecific,
false-positive staining has been reported with anti-EMA as
well as anti-cytokeratin antibodies (Heyderman & McCart-
ney, 1985; Ellis et al., 1989). This underlines the importance
of using both immunocytochemical as well as morphological
criteria before classifying cells as tumour cells (Berger et al.,
1988). There are reports that anti-cytokeratin antibodies are
less sensitive in recognising breast cancer metastases than
anti-EMA (Thor et al., 1988). Therefore, we used an addi-
tional antibody (12-H-12) that does not stain lymphoid cells
(Kaul et al., 1989) as a parallel control: cells were only
classified as tumour cells if they stained positively with the
anti-EMA/anti-cytokeratin cocktail as well as 12-H-12.
Another factor contributing to our detection rate might be
the use of six aspiration sites (Coombes et al., 1983).
Similarly, Diel et al. (1990) were able to raise their detection
rate from 24% to 32% by increasing the number of aspira-
tion sites from 2 to 6. Based on our earlier observations
(confirming the results of Mansi et al., 1987) that the number
of detected tumour cells showed no evidence of prognostic
impact, we did not take into account the actual number of
cells detected. Considering more recent results by Cote et al.
(1991), it might be advisable for future studies of more
patients to include this factor.
The question of whether detected tumour cells are actually
micrometastases or whether they are shed by the primary
tumour or seeded during surgery without bearing any further
clonogenic potential has been raised in the literature (Mansi
et al., 1989). In a median interval of 13 months after primary
surgery, we repeated marrow aspirates in three initially
tumour cell-negative patients: all of them have remained
tumour cell-negative, and up until now none of them has
relapsed. Porro et al. (1988) aspirated bone marrow in 11 of
their patients before as well as after primary surgery. None
of these patients had a different result after surgery. Thus,
they were able to rule out possible tumour cell spread due to
surgical manipulation. Yet another argument against a
merely artificial spread of tumour cells by surgical interven-
tion is the fairly constant percentage of tumour cell detection
in the literature, whether bone marrow aspirates are taken
immediately before (Mansi et al., 1987; Porro et al., 1988;
Cote et al., 1991) or after (Harbeck et al., 1987; Diel et al.,
1992) primary surgery. In our opinion, multiple aspiration
sites as well as the use of cocktails of monoclonal antibodies
are likely to play a far more important role in an increased
detection rate. To examine the viability of the detected
tumour cells, we developed a method for establishing cell
cultures from the marrow aspirates. So far we have succeeded
in growing cell cultures from one tumour cell-positive
patient. The identity of the observed clones was proven
immunocytochemically. In addition to these laboratory
experiments, the follow-up data presented by our group, in
accordance with other groups, strongly suggest that a large
proportion of these cells may be viable and clonogenic. In
our study the relapse rate among tumour cell-positive
patients was almost three times that of tumour cell-negative
patients.
Our follow-up data over a 5-year period confirm that
tumour cell detection in the bone marrow of primary breast
cancer patients is a statistically significant prognostic factor
for early relapse. Its prognostic value is even higher in
predicting bone metastases. Tumour cell-positive patients
also seem to have a worse prognosis with regard to overall
survival, although this trend is not yet significant. Even
within a subgroup defined by 'established' prognostic factors
such as oestrogen receptor-positive patients, tumour cell
presence characterises high-risk patients for a significantly
shorter relapse-free as well as overall survival. In a mul-
tivariate setting, tumour cell presence is a statistically570 N. HARBECK et al.
significant prognostic factor for relapse-free as well as overall
survival. Its prognostic impact outweighs even that of a
clinically important, 'established' prognostic factor such as
lymph node status. Cote et al. (1991) also found tumour cell
presence to be a better predictor for early recurrence than
lymph node status. Mansi et al. (1991) reported after a
median follow-up of 76 months that tumour cell detection
was a significant prognostic factor for relapse-free as well as
overall survival. However, their multivariate analysis showed
that this prognostic impact was less than that of tumour size
or nodal status.
In contrast to other researchers (Mansi et al., 1992; Diel et
al., 1992), we did not obtain a statistically significant correla-
tion between tumour cell detection and 'established' prognos-
tic factors. However, the role of vascular invasion (Mansi et
al., 1987) was not evaluated. In our study, keeping in mind
that the numbers in some subgroups are still small, tumour
cell presence appears to be an independent prognostic factor.
Tumour cell-positive patients seem to be fairly evenly dist-
ributed among the various risk groups, i.e. no excess of
tumour cell-positive patients in a particular risk group was
detected. However, there is one somewhat unexpected excep-
tion: the percentage of tumour cell-positive patients is even
higher among node-negative patients (49%) than among
node-positive patients (36%). The follow-up data of the
node-negative patients resemble those of the total 100 MO
patients: tumour cell-positive patients tend to have a worse
prognosis with shorter relapse-free as well as overall survival.
Porro et al. (1988) also reported a higher detection rate in
node-negative patients, although the difference in their study
is not as evident: 17% vs 14%. Our results tend to confirm
their theoretical considerations. By examining bone marrow
aspirates, one may discover an alternative route for metas-
tasis that bypasses the axillary lymph nodes via the blood-
stream. Thus, there might be two independent but equivalent
routes for metastatic spread in breast cancer (Fisher et al.,
1989b). This concept, together with the presented follow-up
data, emphasises the importance of bone marrow aspirates
for identifying an additional risk group of patients -
especially among node-negative patients - that might have
been missed by sole consideration of the established prognos-
tic factors. Our study also suggests that node-positive,
tumour cell-positive patients might benefit from a more
intensive form of adjuvant therapy (e.g. high-dose
chemotherapy).
Methodological improvements need to be made, since the
detection method is still too time-consuming for routine ap-
plication. Further clinical studies, perhaps on the basis of
national or international collaborations, are warranted in
order to confirm the international follow-up results presented
so far: Only larger patient groups and longer follow-up
periods will allow more detailed subgroup analyses, in partic-
ular among node-negative patients. Such studies will help to
decide whether tumour cell presence is an important prognos-
tic factor by itself or whether it is ofmore value in a panel of
prognostic factors (McGuire et al., 1990). A multicentre
study has now been proposed in Germany in which node-
negative, tumour cell-positive patients will be randomised to
receive adjuvant therapy or not (Funke et al., 1991). The
results of this trial will determine whether adjuvant therapy is
beneficial in patients with tumour cells in their bone mar-
row.
We would like to thank Mrs M. Felber, Mrs H. Gottschalk-Deponte
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